ABSTRACT
1 Despite improvement in early detection and treatment, breast cancer remains the second leading cause of 2 cancer-related death for women in the United States [1] . Breast ductal carcinoma in situ, referred to as DCIS, 3 consists of a heterogeneous group of diseases characterized by a neoplastic mammary lesion that is confined 4 to the ductal system of the breast [2] . DCIS progresses to invasive ductal carcinoma (IDC) through events such 5 as epithelial mesenchymal transition (EMT), basement membrane degradation, controlled inflammatory 6 signaling and other pathways associated with a wound-healing milieu [3] [4] [5] . It is estimated that ~20% of 7 mammography detected breast cancers are DCIS [6] and ACS Facts and Figures indicates ~65,000 cases of 8 DCIS are diagnosed per year [7] . Provided that DCIS is removed surgically, as is standard of care, a woman 9 diagnosed with DCIS without recurrence is more likely to die of other causes than of breast cancer [8] .
10
However, it is estimated that ~15-20%, or ~10-13,000, DCIS patients recur with invasive disease within a 11 decade [9, 10] . Recently identified risk factors for DCIS recurrence include age<40 at diagnosis, African
12
American ethnicity, hormone receptor negativity, and HER2 positivity [8] . However, these high-risk groups only 13 account for 20% of the DCIS patient population [10] . Therefore, identifying additional risk factors for, or markers 14 that will predict, DCIS aggressiveness are extremely important goals for preventing invasive cancer in DCIS 15 patients.
17
There is increasing evidence that inflammation plays a key role in breast cancer progression [11] . One such 18 specific inflammatory pathway is nuclear factor kappa b (NFκB). The NFκB signaling pathway includes five 
23
specifically the canonical heterodimer p50/p65, translocate to the nucleus and bind to promoters of certain 24 target genes, leading to activation of transcription [12, 13] . Two NFκB consensus sites are located in the 25 promoter region of the human PTGS2 gene, which encodes for pro-inflammatory enzyme COX-2 [14] . These
26
NFκB sites are conserved on the 5'-promoter regions in both mouse and human, however the 3' promoter is 27 only found in human [15] . These NFκB consensus sites not only contribute to cancer progression by stimulating 28 and preventing apoptosis, but also the activation of cyclooxygenase 2 (COX-2) mediated signaling [16] . COX-
29
2 is the inducible form of cyclooxygenase, which is the key enzyme involved in the biosynthesis of the pro-
30
inflammatory agent prostaglandin [17] [18] [19] [20] [21] [22] . COX-2 has been implicated in DCIS progression through promotion 31 of mammary tumorigenesis via increases in proliferation, migration, invasion and metastatic spread in pre-
32
clinical models [23] [24] [25] . Additionally, expression of COX-2 is frequently observed in patients with invasive 33 disease and is associated with DCIS recurrence. Furthermore, therapeutic benefit of inhibiting COX-2 has 34 been observed in colon, esophagus, lung, bladder, breast and prostate cancers [19, 20, [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] . Thus, it is 35 logical to expect that inhibition of COX-2 in breast cancer patients could enhance overall prognosis.
37
We have shown that Singleminded-2s (SIM2s;; expressed from SIM2), a member of the bHLH/PAS family of 38 transcription factors, is a tumor suppressor that is expressed in breast epithelial cells and down-regulated in 39 the transition from DCIS to IDC [37] [38] [39] [40] 
53
College of Medicine, Houston, TX, USA). Cells were plated in 6 well plates for RNA isolation experiments 54 according the guidelines from ThermoFisher Scientific. Celecoxib experiment were performed as follows;; cells 55 were first plated in 10uM celecoxib for 24hours, then media was changed and treatment was performed at 1 20uM celecoxib for 24hours and then harvested for analysis. DHA experiments on cell lines were performed as 2 follows;; cells were dosed with 50uM DHA for 24 hours and then harvested for analysis. 
36
Buffer (Promega). Luciferase activity and total protein were measured as described previously [38] .
37
Luciferase activities were normalized to total protein values and are represented as the means ± SE for three 
45

Statistical Analysis
46
To address scientific rigor, all experiments in cell lines and xenografts were conducted in biological triplicates 47 at a minimum, technical duplicates, and repeated three times. Normal distribution was confirmed before 48 conducting unpaired t test. Significance was considered at p <0.05 unless otherwise noted.
50
Results:
51
SIM2s downregulates NFΚB signaling. To test the hypothesis that SIM2 directly affects NFκB/p65 mediated 52 transcription, we co-transfected a reporter plasmid encoding a NFkB binding site upstream of the luciferase 53 gene (5X NFκB-luc) with the p65 subunit along with SIM2s in 293T cells and measured relative light units as a 54 readout for NFκB activity. As expected, p65 strongly activated the reporter construct;; however, this response 55 was blocked by co-transfection of SIM2s (Fig  1A) . To determine the mechanism of this inhibition, the 1 transfection was repeated with a SIM2s expression construct missing the Pro/Ala transcriptional repression 2 domain (SIM2sΔR). This construct also significantly attenuated the activation of the 5X NFκB-luc construct by 3 NFκB/p65, demonstrating that the repression domain of SIM2s is not required for inhibition of NFκB signaling 4 ( Fig  1B) . Alternatively, to determine whether SIM2 modulates expression levels of mediators of the NFκB 5 pathway in our breast cancer cell lines to downregulate signaling, we performed western blot analysis and 6 found that IKKa, IKKb, phosphorylated-p65 and p65 protein levels were all decreased in SIM2s overexpressing 7 SUM159-cells ( Figure  1C ). Similarly, we found that NFκB pathway protein levels were increased in SIM2s (Fig  3A,  Fig  3B) . Moreover, we found that over expression of SIM2s in highly 44 invasive SUM159 cells significantly inhibited PTGS2 expression (Fig  3C) . In our previous studies, we showed 45 that over expression of SIM2s in DCIS.COM cells blocked invasion in vivo, whereas loss of SIM2s or over 46 expression of the protein product of PTGS2, COX-2, resulted in increased invasion and metastasis [23, 42] . To 47 determine the relationship between SIM2s and COX-2 protein expression, we performed immunohistochemical
48
(IHC) analysis for COX-2 in tumors derived from control and SIM2s DCIS.COM xenografts to show that COX-2 49 levels were decreased with over expression of SIM2s in vivo (Fig  3D) . Taken together these results suggest Figure  4A ). Extending these observations IHC analysis of tumors 3 generated from control and shPTGS2 DCIS.COM cells, which are less invasive [23] , revealed an increase in 4 positive nuclear staining for SIM2 with PTGS2 knockdown ( Figure  4B&C ). To determine whether COX-2 5 activity drives the inverse relationship between SIM2 and COX-2 and cell invasion, we treated the highly 6 invasive SUM159 cells with a dose of the selective COX-2 inhibitor, celecoxib, that had previously been shown 7 to decrease invasion of COX-2 expressing cells [23] . We observed a significant increase in SIM2 expression 8 ( Figure  4D ). Additionally, we show that Docosahexaenoic (DHA), a n-3 polyunsaturated fatty acids (PUFA) that 9 can result in a shift to a more anti-inflammatory gene expression profile [44] , and can reduce COX-2 10 expression [45] [46] [47] [48] , significantly increases SIM2s expression ( Figure  4E ). Thus, our driving hypothesis is that 11 reduction of inflammatory pathways via inhibition of activity and/or decreased COX-2 expression results in re-12 expression of SIM2s and may be one mechanism for preventing progression of DCIS to invasive breast Spizzo, G., et al., Correlation of COX--2 and Ep--CAM overexpression in human invasive breast cancer and 1 its impact on survival. Br J Cancer, 2003. 88(4): p. 574--8 
